ReviewPublished 18 September 2026Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessmentNeda Karami · Sebastian Knafl · Heinz D. Wanzenboeck · Sonia Prado-LópezFrontiers in Electronicsdoi 10.3389/felec.2026.1886715
ReviewPublished 12 June 2026Cardio-oncology in multidisciplinary synergy: addressing the rising burden of cancer therapy-related cardiovascular toxicity (CTR-CVT) in advancing oncology practicesPutri Dwi Astuti · Eko Adhi Pangarsa · Andreas Arie Setiawan · Daniel Rizky · Budi Setiawan · Charles Limantoro · Damai Santosa · Catharina SuhartiOncology Reviewsdoi 10.3389/or.2026.1852886
Original ResearchPublished 12 June 2026Electrophysiological mechanisms behind the differential cardiotoxicity of chemotherapeutic agents Bortezomib and CarfilzomibDario Melgari · Serena Calamaio · Anthony Frosio · Rachele Prevostini · Alessio Malacrida · Luigi Anastasia · Carlo Pappone · Gabriella Nicolini · Guido Cavaletti · Ilaria RivoltaFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1774061
Original ResearchPublished 14 April 2026Cardiovascular disease risk among female breast cancer survivors: findings from the National Health Interview Survey (2019–2022)Robina Josiah Willock · Samah R. Nabi · Daniel C. Parks · Brye A. Qaseem · Miriam A. MilesFrontiers in Cancer Control and Societydoi 10.3389/fcacs.2026.1628255
Molecular MedicinePublished 6 January 2025Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse modelCaroline Schoenherr · Stefan Pietzsch · Cristina Barca · Franziska E. Müller · Frauke S. Bahr · Martina Kasten · Andre Zeug · Sergej Erschow · Christine S. Falk · Evgeni Ponimaskin · James T. Thackeray · Denise Hilfiker-Kleiner · Melanie Ricke-HochFrontiers in Molecular Medicinedoi 10.3389/fmmed.2024.1487526
